Latest News - Thermo Fisher Scientific
Top Corporates Hub
Thermo Fisher Scientific
Analysts Appear Bullish on Thermo Fisher (TMO): Is The Stock Really a Buy After Earnings?
31.07.2026 19:09
Thermo Fisher Scientific Inc. (NYSE:TMO) recently announced strong fiscal Q2 2026 results, with revenue growing 10% to $11.99 billion, GAAP diluted EPS rising 9% to $4.68, and adjusted EPS growing 13% to $6.03. The results prompted several analysts to raise their price targets, but after the post-earnings rally, investors must decide whether the recovery story […]
How Thermo Fisher Is Riding Bioproduction and AI-Led Growth Trends
31.07.2026 13:20
TMO is expanding bioproduction, AI tools and clinical data capabilities, but execution will be key as competition intensifies.
Thermo Fisher Scientific's Strong Q2 Not Enough to 'Meaningfully' Change H2 Outlook, RBC Says
24.07.2026 16:52
Thermo Fisher Scientific's (TMO) broad-based improvement in Q2 is not enough to "meaningfully" chang
TMO Q2 Deep Dive: Broad-Based End Market Growth and Strategic Portfolio Moves
24.07.2026 14:09
Life sciences company Thermo Fisher (NYSE:TMO) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 10.5% year on year to $11.99 billion. Its non-GAAP profit of $6.03 per share was 5.6% above analysts’ consensus estimates.
Reading Between The Lines Of DHR's Latest Call
24.07.2026 12:23
Danaher's latest earnings call saw analysts repeatedly test one sore spot in an otherwise solid quarter, and management's answers reveal the key risk for investors now.
Thermo Fisher raises 2026 outlook after 10% growth in Q2
24.07.2026 11:25
Thermo’s Q2 performance was driven by its laboratory products and biopharma services business with profits around $6.69bn equating to a 12% uptick YoY.
Thermo Fisher (TMO) Lands ImmuPharma Kapiglucagon Diabetes Manufacturing Role
24.07.2026 09:08
Thermo Fisher Scientific (NYSE:TMO) has been selected by ImmuPharma as the key drug product and contract development manufacturer for its Kapiglucagon diabetes treatment program. The partnership covers development and manufacturing support for Kapiglucagon, an experimental therapy aimed at addressing diabetes. This agreement adds a new project to Thermo Fisher Scientific’s pharmaceutical services portfolio, focused on complex drug development work. For investors tracking Thermo Fisher...
Thermo Fisher (TMO) Climbs 8.7% on Solid Earnings, Price Target Upgrades
24.07.2026 03:05
Thermo Fisher Scientific Inc. (NYSE:TMO) saw its share prices increase by 8.71 percent on Thursday to close at $572.32 apiece, as investors took heart from the strong earnings performance and a series of price target upgrades for its stock. In the second quarter of the year, the company grew its net income by 7 percent […]
Thermo Fisher Scientific Q2 Earnings Call Highlights
24.07.2026 02:05
Thermo Fisher Scientific (NYSE:TMO) reported stronger-than-expected second-quarter 2026 results and raised its full-year outlook, citing improving customer activity across end markets, broad-based growth and contributions from recent acquisitions. Chairman and Chief Executive Officer Marc Casper sa
TMO Q2 2026 Earnings Call Transcript
24.07.2026 00:29
Organic revenue beat guidance at 5% as pharma and biotech activity strengthened.
Cyclosporiasis: Investing In Biosecurity
23.07.2026 02:05
The global food safety testing market is projected to grow from $28.1 billion in 2026 to $52.9 billion by 2034, driving structural growth for the HTEC index.
Intuitive Surgical Pre-Q2 Analysis: Buy, Hold or Sell the Stock Now?
14.07.2026 13:54
Intuitive Surgical heads into Q2 earnings with strong procedure momentum, da Vinci 5 adoption and expectations for another earnings beat despite margin pressures.
Abbott's Q2 Earnings on Deck: How Should You Play the Stock Now?
14.07.2026 13:34
ABT heads into Q2 earnings results with growth expected across Diagnostics, Devices and EPD, while Nutrition remains a drag. Here's what could shape the results.
OmniAb Names Amechi Nwachuku Chief Operating Officer
13.07.2026 12:00
EMERYVILLE, Calif., July 13, 2026--OmniAb, Inc. (NASDAQ:OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, announces that it has appointed Amechi Nwachuku to the newly-created position of Executive Vice President and Chief Operating Officer, effective today. Mr. Nwachuku will be primarily responsible for managing the strategy, operations and commercial maximization of xPloration®, OmniAb’s proprietary, innovative high-throughp
On the Eve of BIO 2026, Chinese Innovative Assets Trigger a New Wave of Global Collaborations
08.07.2026 16:00
On the eve of the highly anticipated BIO International Convention 2026, the BIOSeedin Summer Innovation Partnering Summit successfully took place in San Diego. Hosted by bioSeedin and proudly supported by strategic partners Thermo Fisher Scientific and ACROBiosystems, the summit was uniquely designed as an international roadshow and licensing matchmaking platform dedicated to showcasing China's differentiated innovative assets.
Cell Culture Media Market worth $12.9 billion by 2033: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG
08.07.2026 15:54
Persistence Market Research, a leading management consulting firm, has released this update on the cell culture media market. These specialized nutrient formulations provide the essential environment for growing and maintaining cells used in biopharmaceutical manufacturing, vaccine production, regenerative medicine, and advanced biomedical research.
9 Health Care Stocks Whale Activity In Today’s Session
08.07.2026 13:35
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will
Thermo Fisher Scientific Receives First FBI Approval for Rapid DNA Crime Scene Profiles Eligible for National CODIS Searches
07.07.2026 12:30
SAN FRANCISCO, July 07, 2026--Thermo Fisher Scientific, the world leader in serving science, today announced that the Applied Biosystems™ RapidINTEL™ Plus Cartridge has received approval from the Federal Bureau of Investigation (FBI) National DNA Index System (NDIS) for use with qualifying forensic crime scene samples. The law enforcement milestone makes Thermo Fisher's Rapid DNA workflow on the RapidHIT ID™ System the first eligible to generate DNA profiles that can be searched against the nati
Surplus Solutions, an NMS Capital Portfolio Company, Accelerates Technical Service Capabilities; Announces Partnership with DCM BioServices
06.07.2026 17:14
Surplus Solutions LLC ("Surplus Solutions"), a portfolio company of NMS Capital ("NMS"), announced today the acquisition of DCM BioServices ("DCM Bio" or the "Company"), a Frederick, Maryland-based provider of laboratory automation maintenance, repair, technical support, and integration solutions. The acquisition expands Surplus Solutions' technical service capabilities and supports the Company's continued growth in the biotechnology, pharmaceutical, and life sciences sectors. Terms of the trans
Medpace: The Recovery Narrative Looks Premature
06.07.2026 14:28
Medpace's outlook turns cautious as bookings, backlog, and cancellations worsen vs. CRO peers. Click for more on MEDP stock.